Boothwyn Pharmacy LLC

Has Boothwyn Pharmacy LLC received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued Boothwyn Pharmacy LLC a warning letter naming semaglutide and tirzepatide, dated Jan 16, 2026, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” openFDA also lists 3 drug recall reports for the firm naming semaglutide.

FDA records in this index name Boothwyn Pharmacy LLC from Jul 9, 2025 to Jan 16, 2026.

Names in FDA records
Boothwyn Pharmacy LLC; Boothwyn Pharmacy, LLC
Type named in FDA records
Compounding pharmacy
FDA warning letters
1
Drug recall reports
3
Drugs named
Semaglutide, Tirzepatide
Latest record
Jan 16, 2026

FDA warning letters

Later letters FDA listsLetter
Jan 16, 2026Compounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Drug recalls

Record
Jul 9, 2025Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn PharmacySubpotent DrugClass IIOngoingD-0608-2025
Jul 9, 2025Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn PharmacySubpotent DrugClass IIOngoingD-0606-2025
Jul 9, 2025Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn PharmacySubpotent DrugClass IIOngoingD-0609-2025

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

Boothwyn Pharmacy LLC, Kennett Square, PA (503A)

5 listed actions, including 3 Form 483s and 1 warning letter (2021 to 2026).

Document
Jan 16, 2026Warning letterWarning Letter Issued 01/16/2026fda.gov
Jun 9, 2025Form 483483 Issued 06/09/2025fda.gov
May 13, 2024Regulatory meetingRegulatory Meeting Held 05/13/2024Not linked by FDA
Sep 12, 2023Amended Form 483Amended 483 Issued 9/12/2023FDA copy (archived)
Sep 8, 2021Form 483483 Issued 09/08/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Boothwyn Pharmacy LLC, Kennett Square, PA.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.